S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Karen H. Albritton, MD
Dana-Farber Cancer Institute
Study Chair - R. Lor Randall, MD, FACS
University of Utah
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
101 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
- University of California Davis Cancer Center
Davis, California, United States
- Contra Costa Regional Medical Center
Martinez, California, United States
- St. Anthony Central Hospital
Denver, Colorado, United States
- University of Colorado Cancer Center at University of Colorado Health Sciences Center
Denver, Colorado, United States
- Montrose Memorial Hospital Cancer Center
Montrose, Colorado, United States
- St. Anthony North Hospital
Westminster, Colorado, United States
- Exempla Lutheran Medical Center
Wheat Ridge, Colorado, United States
- Ccop - Atlanta Regional
Atlanta, Georgia, United States
- Northside Hospital Cancer Center
Atlanta, Georgia, United States
- Piedmont Hospital
Atlanta, Georgia, United States
- Saint Joseph'S Hospital of Atlanta
Atlanta, Georgia, United States
- Wellstar Cobb Hospital
Austell, Georgia, United States
- Charles B. Eberhart Cancer Center at Dekalb Medical Center
Decatur, Georgia, United States
- Gwinnett Medical Center
Lawrenceville, Georgia, United States
- Kennestone Cancer Center at Wellstar Kennestone Hospital
Marietta, Georgia, United States
- Southern Regional Medical Center
Riverdale, Georgia, United States
- Cardinal Bernardin Cancer Center at Loyola University Medical Center
Maywood, Illinois, United States
- Regional Cancer Center at Memorial Medical Center
Springfield, Illinois, United States
- St. Francis Hospital and Health Centers
Beech Grove, Indiana, United States
- Mcfarland Clinic, P.C.
Ames, Iowa, United States
- Baton Rouge General Regional Cancer Center
Baton Rouge, Louisiana, United States
- Mary Bird Perkins Cancer Center - Baton Rouge
Baton Rouge, Louisiana, United States
- Mbccop - Lsu Health Sciences Center
New Orleans, Louisiana, United States
- Medical Center of Louisiana - New Orleans
New Orleans, Louisiana, United States
- University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
- Battle Creek Health System Cancer Care Center
Battle Creek, Michigan, United States
- Mecosta County General Hospital
Big Rapids, Michigan, United States
- Ccop - Grand Rapids
Grand Rapids, Michigan, United States
- Lacks Cancer Center at Saint Mary'S Mercy Medical Center
Grand Rapids, Michigan, United States
- Metropolitan Hospital
Grand Rapids, Michigan, United States
- Spectrum Health Cancer Care - Butterworth Campus
Grand Rapids, Michigan, United States
- Spectrum Health Hospital - Blodgett Campus
Grand Rapids, Michigan, United States
- Holland Community Hospital
Holland, Michigan, United States
- Hackley Hospital
Muskegon, Michigan, United States
- Northern Michigan Hospital
Petoskey, Michigan, United States
- Munson Medical Center
Traverse City, Michigan, United States
- Ccop - Montana Cancer Consortium
Billings, Montana, United States
- Deaconess Billings Clinic - Downtown
Billings, Montana, United States
- Deaconess Billings Clinic Cancer Center
Billings, Montana, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Dec 2003
- Primary completion
- 31 Jul 2007
- Completion
- 31 Aug 2009
- Last update posted
- 6 Nov 2017
- Registered enrollment
- 24
- Registry id
- NCT00068367
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.